The U.S. House of Representatives last week failed to advance once-promising legislation that effectively would have banned asbestos, frustrating advocates once again. H.R.
Pharmaceutical giant Johnson & Johnson has agreed to pay more than $100 million to settle more than a thousand lawsuits claiming its iconic talc-based…
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma.
While the incidence of malignant mesothelioma in the United States continued its gradual decline, the tendency to sue for damages drastically increased in recent…
A much-anticipated, phase III clinical trial studying the use of gene therapy to combat pleural mesothelioma cancer has made a promising start. Interest…
The Science Advisory Committee on Chemicals found considerable failings and an underestimation of danger to the general public in a draft risk evaluation of…
Georgia-Pacific has pledged $1 billion to fund an asbestos trust for bankrupt affiliate Bestwall LLC, clearing the path to a settlement of longstanding liability…
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II…
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination.
